Lansoprazole: In the treatment of gastro-oesophageal reflux disease in children and adolescents

Drugs

Volumn 65, Issue 15, 2005, Pages 2129-2135

  Croom, Katherine F ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; GASTRIN; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

ABDOMINAL PAIN; ANOREXIA; AREA UNDER THE CURVE; ASTHENIA; CLINICAL FEATURE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DYSPNEA; ESOPHAGUS PH; GASTRIN BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MIGRAINE; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID SECRETION; STOMACH PH; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ANTI-ULCER AGENTS; CHILD; CHILD, PRESCHOOL; GASTROESOPHAGEAL REFLUX; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; INFANT; OMEPRAZOLE;

EID: 26944432283     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565150-00005     Document Type: Review

References (26)

1. Hassall E. Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children. J Pediatr 2005; 146 (3 Suppl.): S3-S12
2. Rudolph CD, Mazur LJ, Liptak GS, et al. Pediatric GE reflux clinical practice guidelines. J Pediatr Gastroenterol Nutr 2001; 35 Suppl. 2: S1-31
3. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005 Jan; 100 (1): 190-200
4. Barradell LB, Faulds D, McTavish D. Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44 (2): 225-50
5. Spencer CM, Faulds D. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994; 48 (3): 404-30
6. Langtry HD, Wilde MI. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997; 54 (3): 473-500
7. Matheson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs 2001; 61 (12): 1801-33
8. TAP Pharmaceutical Products Inc. Prevacid (lansoprazole) package insert (US). July 2004 [online]. Available from URL: http://www.tap.com [Accessed 2005 Sep 25]
9. Gremse D, Winter H, Tolia V, et al. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2002; 35 Suppl. 4: S319-26
10. Gunasekaran T, Gupta S, Gremse D, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. J Pediatr Gastroenterol Nutr 2002; 35 Suppl. 4: S327-35
11. Fiedorek S, Tolia T, Gold BD, et al. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2005 Mar; 40 (3): 319-27
12. Book L, Chiu Y-L, Pilmer B, et al. Effect of lansoprazole on intraesophageal pH in children with pathologic acid reflux [abstract no. S1276]. Gastroenterology 2002 Apr; 122 Suppl. 1: A197.
13. Plus poster presented at Digestive Disease Week; 2002 May 19-22; San Francisco (CA)
14. Miner P, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98 (12): 2616-20
15. Armstrong D, Marshall JK, Chiba N, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004 [online]. Available from URL: http://www.cag-acg.org [Accessed 2005 Sep 23]
16. Stolte M, Meining A, Seifert E, et al. Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach. Pathol Res Pract 2000; 196: 9-13
17. Stolte M, Vieth M, Schmitz JM, et al. Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus. Scand J Gastroenterol 2000; 35: 1125-30
18. Faure C, Michaud L, Shaghaghi EK, et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001 Sep; 15 (9): 1397-402
19. Tran A, Rey E, Pons G, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther 2002 May; 71 (5): 359-67
20. Freston JW, Chiu Y-L, Mulford DJ, et al. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther 2003 Feb 1; 17: 361-7
21. Gremse DA, Donnelly JR, Kukulka MJ, et al. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe. Aliment Pharmacol Ther 2004 Jun 1; 19 (11): 1211-5
22. Tolia V, Ferry G, Gunasekaran T, et al. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35 Suppl. 4: S308-18
23. Franco MT, Salvia G, Terrin G, et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis 2000 Nov; 32 (8): 660-6
24. Tolia V, Johnston G, Stolle J, et al. Flavor and taste of lansoprazole strawberry-flavored delayed-release oral suspension preferred over ranitidine peppermint-flavored oral syrup in children aged between 5-11 years. Paediatr Drugs 2004; 6 (2): 127-31
25. Tolia V, Han C, North JD, et al. Taste comparisons for lansoprazole strawberry-flavoured delayed-release orally disintegrating tablet and ranitidine peppermint-flavoured syrup in children. Clin Drug Invest 2005; 25 (5): 285-92
26. Tolia V, Fitzgerald J, Hassall E, et al. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35 Suppl. 4: S300-7